QuantRx Biomedical Corporation (OTC: QTXB), a developer and marketer of diagnostic products, with a strong intellectual property portfolio, announced the completion of a material agreement with FluoroPharma, Inc., the leader in the discovery, development, and commercialization of innovative molecular imaging agents for the Positron Emission Tomography (PET) market. FluoroPharma's current focus is the development of novel cardiovascular imaging agents that allow for the efficient detection and assessment of acute and chronic forms of Coronary Artery Disease (CAD).
